Furthermore, imatinib or nilotinib, which are FDA-approved c-Abl inhibitors, showed neuroprotective effects when administered in animal models of PD and AD (Cancino et al., 2008; Hebron et al., 2013). The gene discussed is ABL1; the disease is Alzheimer disease.